Carl Zeiss Meditec’s Revenues Grow 7.5 Percent in Latest Quarter

August 11, 2017: By Jon Swedien

ZeissCarl Zeiss Meditec’s revenues for Q3-2016/17 were €277.2 million ($325.8 million, as of Aug. 10, 2017), the German company reported Aug. 7.

That marks a 7.5 percent increase over the company’s Q3-2015/16 revenues.

Zeiss’ revenues during the first nine months of its 2016/17 fiscal year totaled €864.7 million ($1 billion, as of Aug. 10, 2017), marking an 8.3 percent (7.2 percent, cc) increase over the same three quarters from the previous year, Zeiss said.

Ophthalmology sales lead the way for much of the growth, the company said.

Zeiss’ ophthalmic devices strategic business unit recorded €639.9 million ($752 million, as of Aug. 10, 2017), in revenues during the first nine month of Zeiss’ current fiscal year, the company said.

That marks a 9.2 percent (82 percent, cc) increase over the first nine months of the company’s previous fiscal year, Zeiss said.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

FDA Advisory Panel Recommends Aerie’s Rhopressa for Glaucoma Patients

FDA Panel Unanimously Backs Spark’s Luxturna as Retinal Gene Therapy

PanOptica Secures $11 Million to Advance Topical Anti-VEGF Eye Drop for Neovascular AMD

Nicox and pSivida to Collaborate to Develop a Sustained Release Drug to Lower IOP

Azura Nets $16 Million in Series B Funding for Dry Eye Treatment

Alcon’s AcrySof Intraocular Lens Reaches 100 Million Implants

Notal Vision’s ForeseeHome Reaches Milestone of 3 Million Tests

FDA to Review Spark’s Retinal Gene Therapy Candidate Oct. 12

Alcon’s AutonoMe IOL Injector Gains CE Mark Approval

Shire Sues Allergan, Claiming Bundling Tactics Block Restasis Competitors

Allergan Decries ‘Unfair’ Patent Challenge Process as US House Launches Probe of Tribe Deal

FDA Warns that Vancomycin Eye Injections May Lead to Blindness

Alcon to Launch Clareon IOL at ESCRS Meeting

Bribery Trial Testimony Focuses on Melgen’s Billing for Lucentis

VSY Biotechnology to Launch AcrivaUD Trinova Trifocal IOL at ESCRS Meeting

Valeant Launches $1 Billion Private Senior Notes Offering

STAAR Surgical Appoints Scott Barnes, MD, as New CMO

Aerie Acquires Envisia Technology for $25M to Advance Retinal Program

Carl Zeiss Meditec Announces Milestone of 1 Million SMILE Procedures

Maryland Team Wins First Phase of NEI Contest to Create Human Retina

Coming soon

2017 Refractive Surgery Report: A Global Market Analysis for 2016 to 2022